-

XCUR SHAREHOLDERS: Robbins LLP Informs Investors of Class Action Against Exicure, Inc. (XCUR)

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Exicure, Inc. (NASDAQ: XCUR) securities between March 11, 2021 and November 15, 2021, for violations of the Securities Exchange Act of 1934. Exicure is a clinical stage biotechnology company that develops therapeutics for neurology, immune-oncology, inflammatory diseases, and other genetic disorders based on its proprietary spherical nucleic acid technology.

If you suffered a loss due to Exicure, Inc.'s misconduct, click here.

Exicure, Inc. (XCUR) Failed to Disclose Improprieties Associated with its Preclinical Program for the Treatment of Friedreich's Ataxia

According to the complaint, defendants failed to disclose that there had been certain improprieties in Exicure's preclinical program for the treatment of Friedreich's ataxia and that there was a material risk that data from the preclinical program would not support continued clinical development.

On November 15, 2021, Exicure filed a Form 12b-25 with the SEC stating that it could not timely file its quarterly report ended September 30, 2021. It explained it was investigating "a claim made by a former Company senior researcher regarding alleged improprieties that researcher claims to have committed with respect to the Company's XCUR-FXN preclinical program for the treatment of Friedreich's ataxia." On this news, the Company's stock price fell 28%, to close at $1.07 per share on November 16, 2021.

If you acquired shares of Exicure, Inc. (XCUR) securities between March 11, 2021 and November 15, 2021, you have until February 11, 2022, to ask the court to appoint you lead plaintiff for the class.

Representation is on a contingency fee basis. Shareholders pay no fees or costs.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Exicure, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:XCUR

Release Summary
Exicure, Inc. (XCUR) Failed to Disclose Improprieties Associated with its Preclinical Program for the Treatment of Friedreich's Ataxia
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Ramaco Resources, Inc. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ramaco Resources, Inc. (NASDAQ: METC) securities between July 31, 2025 and October 23, 2025. Ramaco engages in the mining, development, and sale of coal and rare earth minerals. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations th...

CPNG Class Action Alert: Robbins LLP Reminds Investors with Losses in Coupang, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Coupang, Inc. (NYSE: CPNG) securities between April 6, 2025 and December 16, 2025. Coupang describes itself as one of the fastest-growing technology and commerce companies in the world, providing retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Cou...

Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTGN Should Contact Robbins LLP for Information About Leading the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025. Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. For more information, submit a form, email attorney Aaron Dumas...
Back to Newsroom